Cellenkos' umbilical cord blood-derived T regulatory cell therapy significantly slowed ALS disease progression, reducing monthly ALSFRS-R score decline from -1.66 to -0.41 points during treatment.
Cellenkos' novel T regulatory cell therapy CK0801 received FDA Orphan Drug Designation for treating aplastic anemia, a rare bone marrow failure disorder affecting approximately 5,000 patients in the US.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.